Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Uveal Melanoma: A Review of the Literature

Uveal Melanoma: A Review of the Literature Melanomas affecting different components of the uvea occur with differing frequencies and clinical presentations. Uveal melanoma is diagnosed via funduscopic exam and ancillary tests. These lesions may present with visual findings or incidental findings on physical exam. Metastasis occurs in approximately half of all patients with primary uveal melanoma. The liver is the most common site of metastasis. Enucleation was at one time considered the definitive local treatment for primary uveal melanoma, but has been largely replaced by other therapeutic procedures that aim to prevent metastasis while preserving vision. Unfortunately, metastasis of uveal melanoma almost always proves to be fatal. The current treatment of metastatic uveal melanoma is limited by the intrinsic resistance of uveal melanoma to conventional systemic therapies. Advancements in molecular biology have resulted in the identification of a number of promising prognostic and therapeutic targets. Early detection and therapy are important factors in disease survival. It is imperative that the treating physician be familiar with the clinical features of uveal melanoma and distinguish it from mimickers in order to ensure effective and timely treatment. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Oncology and Therapy Springer Journals

Uveal Melanoma: A Review of the Literature

Download PDF
18 pages

Loading next page...
 
/lp/springer-journals/uveal-melanoma-a-review-of-the-literature-TlxGj4t4l0
Publisher
Springer Journals
Copyright
Copyright © 2018 by The Author(s)
Subject
Medicine & Public Health; Internal Medicine
ISSN
2366-1070
eISSN
2366-1089
DOI
10.1007/s40487-018-0056-8
Publisher site
See Article on Publisher Site

Abstract

Melanomas affecting different components of the uvea occur with differing frequencies and clinical presentations. Uveal melanoma is diagnosed via funduscopic exam and ancillary tests. These lesions may present with visual findings or incidental findings on physical exam. Metastasis occurs in approximately half of all patients with primary uveal melanoma. The liver is the most common site of metastasis. Enucleation was at one time considered the definitive local treatment for primary uveal melanoma, but has been largely replaced by other therapeutic procedures that aim to prevent metastasis while preserving vision. Unfortunately, metastasis of uveal melanoma almost always proves to be fatal. The current treatment of metastatic uveal melanoma is limited by the intrinsic resistance of uveal melanoma to conventional systemic therapies. Advancements in molecular biology have resulted in the identification of a number of promising prognostic and therapeutic targets. Early detection and therapy are important factors in disease survival. It is imperative that the treating physician be familiar with the clinical features of uveal melanoma and distinguish it from mimickers in order to ensure effective and timely treatment.

Journal

Oncology and Therapy – Springer Journals

Published: Feb 6, 2018

References

  • Uveal melanoma
    Spagnolo, F; Caltabiano, G; Queirolo, P
  • Epidemiology and management of uveal melanoma
    Yonekawa, Y; Kim, IK
  • Emerging insights into the molecular pathogenesis of uveal melanoma
    Landerville, S; Agapova, OA; Harbour, JW
  • Choroidal melanoma: clinical features, classification, and top 10 pseudomelanomas
    Shields, CL; Manalac, J; Das, C; Ferguson, K; Shields, JA
  • Treatment of primary intraocular melanoma
    Damato, B
  • The national cancer data base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade
    Chang, AE; Karnell, LH; Menck, HR
  • Incidence of uveal melanoma in Europe
    Virgili, G; Gatta, G; Ciccolallo, L
  • Epidemiology of extracutaneous melanoma in the Netherlands
    Koomen, ER; Vries, E; Kempen, LC
  • An epidemiological study of posterior uveal melanoma in Israel, 1961–1989
    Iscovich, J; Ackerman, C; Andreev, H; Pe’er, J; Steinitz, R
  • Uveal and conjunctival malignant melanoma in Denmark, 1943–97: incidence and validation study
    Isager, P; Østerlind, A; Engholm, G
  • Uveal melanoma: trends in incidence, treatment, and survival
    Singh, AD; Turell, ME; Topham, AK
  • Clinical spectrum and prognosis of uveal melanoma based on age at presentation in 8,033 cases
    Shields, CL; Kaliki, S; Furuta, M; Mashayekhi, A; Shields, JA
  • Congenital melanoma of the anterior uvea
    Greer, CH
  • Uveal melanoma in Israel in the last two decades: characterization, treatment and prognosis
    Frenkel, S; Hendler, K; Pe’er, J
  • Population-based incidence of uveal melanoma in various races and enthic groups
    Hu, D-N; Yu, G-P; McCormick, SA; Schneider, S; Finger, PT
  • Host factors, UV radiation, and risk of uveal melanoma. A case–control study
    Seddon, JM; Gragoudas, ES; Glynn, RJ; Egan, KM; Albert, DM; Blitzer, PH
  • The association between host susceptibility factors and uveal melanoma: a meta-analysis
    Weis, E; Shah, CP; Lajous, M; Shields, JA; Shields, CL
  • Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26
    Diener-West, M; Reynolds, SM; Agugliaro, DJ
  • Metastatic uveal melanoma
    Singh, AD; Borden, EC
  • Metastatic uveal melanoma therapy: current options
    Bedikian, AY
  • Prognostic factors in uveal melanoma
    Singh, AD; Shields, CL; Shields, JA
  • Genomic profile of 320 uveal melanoma cases: chromosome 8p-loss and metastatic outcome
    Ewens, KG; Kanetsky, PA; Richards-Yutz, J
  • Genotypic profiling of 452 choroidal melanomas with multiplex ligation-dependent probe amplification
    Damato, B; Dopierala, JA; Coupland, SE
  • Progress in the management of patients with uveal melanoma. The 2012 Ashton Lecture
    Damato, B
  • Targeted therapy for uveal melanoma
    Triozzi, PL; Eng, C; Singh, AD
  • Uveal melanoma: evidence for adjuvant therapy
    Choudhary, MM; Triozzi, PL; Singh, AD
  • Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS
    Zuidervaart, W; Nieuwpoort, F; Stark, M
  • Mutations in GNA11 in uveal melanoma
    Raamsdonk, CD; Griewank , KG; Crosby, MB
  • Mutational profile of GNAQQ209 in human tumors
    Lamba, S; Felicioni, L; Buttitta, F
  • Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma
    Moore, AR; Ceraudo, E; Sher, JJ
  • Deep sequencing of uveal melanoma identifies a recurrent mutation in PLCB4
    Johansson, P; Aoude, LG; Wadt, K
  • Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma
    Harbour, JW; Roberson, ED; Anbunathan, H; Onken, MD; Worley, LA; Bowcock, AM
  • Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3
    Martin, M; Maßhöfer, L; Temming, P
  • Dissecting karyotypic patterns in malignant melanomas: temporal clustering of losses and gains in melanoma karyotypic evolution
    Höglund, M; Gisselsson, D; Hansen, GB
  • Tumor classification based on gene expression profiling shows that uveal melanomas with and without monosomy 3 represent two distinct entities
    Tschentscher, F; Hüsing, J; Hölter, T
  • Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death
    Onken, MD; Worley, LA; Ehlers, JP; Harbour, JW
  • Prognostic implications of monosomy 3 in uveal melanoma
    Prescher, G; Bornfeld, N; Hirche, H; Horsthemke, B; Jöckel, KH; Becher, R
  • Fine mapping of chromosome 3 in uveal melanoma: identification of a minimal region of deletion on chromosomal arm 3p25.1–p25.2
    Parrella, P; Fazio, VM; Gallo, AP; Sidransky, D; Merbs, SL
  • Partial deletions of the long and short arm of chromosome 3 point to two tumor suppressor genes in uveal melanoma
    Tschentscher, F; Prescher, G; Horsman, DE
  • Abnormalities of chromosomes 3 and 8 in posterior uveal melanoma correlate with prognosis
    Sisley, K; Rennie, IG; Parsons, MA
  • Allelotype of posterior uveal melanoma: implications for a bifurcated tumor progression pathway
    Parrella, P; Sidransky, D; Merbs, SL
  • Concomitant loss of chromosome 3 and whole arm losses and gains of chromosome 1, 6, or 8 in metastasizing primary uveal melanoma
    Aalto, Y; Eriksson, L; Seregard, S; Larsson, O; Knuutila, S
  • An accurate, clinically feasible multi-gene expression assay for predicting metastasis in uveal melanoma
    Onken, MD; Worley, LA; Tuscan, MD; Harbour, JW
  • PRAME as an independent biomarker for metastasis in uveal melanoma
    Field, MG; Decatur, CL; Kurtenbach, S
  • Microvascular loops and networks as prognostic indicators in choroidal and ciliary body melanomas
    Mäkitie, T; Summanen, P; Tarkkanen, A; Kivelä, T
  • Microvascular density in predicting survival of patients with choroidal and ciliary body melanoma
    Mäkitie, T; Summanen, P; Tarkkanen, A; Kivelä, T
  • Microvessel count predicts survival in uveal melanoma
    Foss, AJE; Alexander, RA; Jefferies, LW
  • Integrin expression in uveal melanoma differs from cutaneous melanoma
    Berge, PJM; Danen, EHJ; Muijen, GNP; Jager, MJ; Ruiter, DJ
  • Clinical significance of alpha(v)beta3 integrin and intercellular adhesion molecule-1 expression in cutaneous malignant melanoma lesions
    Natali, PG; Hamby, CV; Felding-Habermann, B
  • Matrix metalloproteinase-2 (MMP-2) immunoreactive protein—a new prognostic marker in uveal melanoma?
    Väisänen, A; Kallioinen, M; Dickhoff, K; Laatikainen, L; Höyhtyä, M; Turpeenniemi-Hujanen, T
  • Metastasis of uveal melanoma millimeter-by-millimeter in 8033 consecutive eyes
    Shields, CL; Furuta, M; Thangappan, A
  • Ring melanoma of the ciliary body: report on twenty-three patients
    Demirci, H; Shields, CL; Shields, JA; Honavar, SG; Eagle, RC
  • Ciliary body melanoma—a particularly rare type of ocular tumor
    Costache, M; Patrascu, OM; Adrian, D
  • Iris melanoma. Nevus or malignancy
    Kersten, R; Tse, D; Anderson, R
  • Iris melanoma: risk factors for metastasis in 169 consecutive patients
    Shields, CL; Shields, JA; Materin, M; Gershenbaum, E; Singh, AD; Smith, A
  • Natural course of melanocytic tumors of the iris
    Territo, C; Shields, CL; Shields, JA; Augsburger, JJ; Schroeder, RP
  • Uveal melanoma: estimating prognosis
    Kaliki, S; Shields, CL; Shields, JA
  • The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: initial mortality findings. COMS Report No. 18
    Diener-West, M; Earle, JD; Fine, SL
  • A, review of mortality from choroidal melanoma: II. A meta-analysis of 5-year mortality rates following enucleation, 1966 through 1988
    Diener-West, M; Hawkins, BS; Markowitz, JA; Schachat, AP
  • Very long-term prognosis of patients with malignant uveal melanoma
    Kujala, E; Mäkitie, T; Kivelä, T
  • Biologic distinctions between cure and time to death in 2892 patients with intraocular melanoma
    Gamel, JW; McLean, IW; McCurdy, JB
  • Survival in patients with uveal melanoma in Europe
    Virgili, G; Gatta, G; Ciccolallo, L
  • Diffuse versus nondiffuse small (≤ 3 mm thickness) choroidal melanoma: comparative analysis in 1,751 cases. The 2012 F. Phinizy Calhoun lecture
    Shields, CL; Kaliki, S; Furuta, M; Shields, JA
  • Association of ocular and oculodermal melanocytosis with the rate of uveal melanoma metastasis: analysis of 7872 consecutive eyes
    Shields, CL; Kaliki, S; Livesey, M
  • Uveal melanoma. Location, size, cell type, and enucleation as risk factors in metastasis
    McLean, LCIW; Foster, WD; Zimmerman, LE
  • A reappraisal of the significance of largest basal diameter of posterior uveal melanoma
    Damato, B; Coupland, SE
  • Cytogenetics of uveal melanoma: a 7-year clinical experience
    Damato, B; Duke, C; Coupland, SE
  • International validation of the American Joint Committee on Cancer’s 7th edition classification of uveal melanoma
    Simpson, E; Gallie, BL; Saakyan, S
  • American Joint Committee on Cancer classification of posterior uveal melanoma (tumor size category) predicts prognosis in 7731 patients
    Shields, CL; Kaliki, S; Furuta, M; Fulco, E; Alarcon, C; Shields, JA
  • Things that go bump in the light. The differential diagnosis of posterior uveal melanomas. The Duke Elder Lecture 2001
    Rennie, I
  • The differential diagnosis of posterior uveal melanoma
    Shields, J; Augsburger, J; Brown, G; Rf, S
  • Pseudomelanomas of the posterior uveal tract: the 2006 Taylor R. Smith Lecture
    Shields, JA; Mashayekhi, A; Ra, S; Shields, CL
  • Factors predictive of growth and treatment of small choroidal melanoma: COMS Report No. 5. The Collaborative Ocular Melanoma Study Group
    Collaborative, T; Melanoma, O
  • Is observation really appropriate for small choroidal melanomas
    Augsburger, JJ
  • Risk factors for growth and metastasis of small choroidal melanocytic lesions
    Shields, CL; Shields, JA; Kiratli, H; Potter, P; Cater, JR
  • Prognostic factors in small malignant melanomas of choroid and ciliary body
    McLean, MJ; Foster, WD; Zimmerman, LE
  • The American Brachytherapy Society recommendations for brachytherapy of uveal melanomas
    Nag, S; Quivey, JM; Earle, JD; Followill, D; Fontanesi, J; Finger, PT
  • Statistical analysis of follow-up data concerning uveal melanomas, and the influence of enucleation
    Zimmerman, LE; McLean, I; Foster, WD
  • Long-term surgical outcome of posterior choroidal melanoma treated by endoresection
    Karkhaneh, R; Chams, H; Amoli, FA
  • Long-term outcome of primary endoresection of choroidal melanoma
    Konstantinidis, L; Groenewald, C; Coupland, SE; Damato, B
  • Uveal melanoma: evidence for efficacy of therapy
    Afshar, AR; Damato, BE
  • Local resection of uveal melanoma
    Damato, BE
  • Histopathology of eyes enucleated after endoresection of choroidal melanoma
    Hadden, PW; Hiscott, PS; Damato, BE
  • Local tumor control after 106Ru brachytherapy of choroidal melanoma
    Damato, B; Patel, I; Campbell, IR; Mayles, HM; Errington, RD
  • Charged particle radiation therapy for uveal melanoma: a systematic review and meta-analysis
    Wang, Z; Nabhan, M; Schild, SE
  • Combined proton beam radiotherapy and transpupillary thermotherapy for large uveal melanomas: a randomized study of 151 patients
    Desjardins, L; Lumbroso-Le Rouic, L; Levy-Gabriel, C
  • Proton beam radiotherapy of choroidal melanoma: the Liverpool–Clatterbridge experience
    Damato, B; Kacperek, A; Chopra, M; Campbell, IR; Errington, RD
  • Intraoperative echographic localization of iodine-125 episcleral plaque for brachytherapy of choroidal melanoma
    Tabandeh, H; Chaudhry, NA; Murray, TG
  • Eccentric ruthenium plaque radiotherapy of posterior choroidal melanoma
    Russo, A; Laguardia, M; Damato, B
  • Visual acuity after ruthenium106 brachytherapy of choroidal melanomas
    Damato, B; Patel, I; Campbell, IR; Mayles, HM; Errington, RD
  • The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: IV. Local treatment failure and enucleation in the first 5 years after brachytherapy. COMS report no. 19
    Jampol, LM; Moy, CS; Murray, TG
  • Primary transpupillary thermotherapy for small choroidal melanoma in 256 consecutive cases: outcomes and limitations
    Shields, CL; Shields, JA; Perez, N; Singh, AD; Cater, J
  • Local tumor control and morbidity after one to three fractions of stereotactic external beam irradiation for uveal melanoma
    Zehetmayer, M; Kitz, K; Menapace, R
  • MRI in the detection of hepatic metastases from high-risk uveal melanoma: a prospective study in 188 patients
    Marshall, E; Romaniuk, C; Ghaneh, P
  • Treatment of liver metastases from uveal melanoma
    Rivoire, M; Kodjikian, L; Baldo, S; Kaemmerlen, P; Négrier, S; Grange, JD
  • Surgical management of liver metastases from uveal melanoma: 16 years’ experience at the Institut Curie
    Mariani, P; Piperno-Neumann, S; Servois, V
  • Long-term survival of uveal melanoma patients after surgery for liver metastases
    Frenkel, S; Nir, I; Hendler, K
  • Hepatic resection for noncolorectal nonendocrine liver metastases: analysis of 1,452 patients and development of a prognostic model
    Adam, R; Chiche, L; Aloia, T
  • Hepatic resection for metastatic melanoma in the Netherlands: survival and prognostic factors
    Ridder, J; Walsum, M; Verhoef, C; Nagtegaal, I; Wilt, J
  • Hepatectomy for noncolorectal non-neuroendocrine metastatic cancer: a multi-institutional analysis
    Groeschl, RT; Nachmany, I; Steel, JL
  • Hepatic resection for metastatic melanoma: distinct patterns of recurrence and prognosis for ocular versus cutaneous disease
    Pawlik, TM; Zorzi, D; Abdalla, EK
  • Liver resection for metastatic melanoma: Equivalent survival for cutaneous and ocular primaries
    Ryu, SW; Saw, R; Scolyer, RA; Crawford, M; Thompson, JF; Sandroussi, C
  • Liver resection for metastatic melanoma with postoperative tumor-infiltrating lymphocyte therapy
    Ripley, RT; Davis, JL; Klapper, JA
  • Metastatic melanoma to the liver
    Agarwala, SS; Eggermont, AMM; O’Day, S; Zager, JS
  • Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: experience in 101 patients
    Peters, S; Voelter, V; Zografos, L
  • Hepatic arterial fotemustine chemotherapy in patients with liver metastases from cutaneous melanoma is as effective as in ocular melanoma
    Siegel, R; Hauschild, A; Kettelhack, C; Kähler, KC; Bembenek, A; Schlag, PM
  • Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial
    Leyvraz, S; Piperno-Neumann, S; Suciu, S
  • Liver metastases from melanoma: hepatic intra-arterial chemotherapy
    Farolfi, A; Ridolfi, L; Guidoboni, M
  • Phase I/II randomized trial of intrahepatic arterial infusion chemotherapy with cisplatin and chemoembolization with cisplatin and polyvinyl sponge in patients with ocular melanoma metastatic to the liver
    Agarwala, SS; Panikkar, R; Kirkwood, JM
  • Transarterial hepatic chemoperfusion of uveal melanoma metastases: furvival and response to treatment
    Heusner, TA; Antoch, G; Wittkowski-Sterczewski, A
  • Treatment of disseminated ocular melanoma with sequential fotemustine, interferon alpha, and interleukin 2
    Becker, JC; Terheyden, P; Kämpgen, E
  • Immunoembolization of malignant liver tumors, including uveal melanoma, using granulocyte-macrophage colony-stimulating factor
    Sato, T; Eschelman, DJ; Gonsalves, CF
  • Hepatic artery chemoembolization in patients with ocular melanoma metastatic to the liver: response, survival, and prognostic factors
    Gupta, S; Bedikian, AY; Ahrar, J
  • Chemoembolization of the hepatic artery with BCNU for metastatic uveal melanoma: results of a phase II study
    Patel, K; Sullivan, K; Berd, D
  • Transarterial chemoembolization of liver metastases from uveal melanoma after failure of systemic therapy: toxicity and outcome
    Schuster, R; Lindner, M; Wacker, F
  • Hepatic arterial chemoembolization for management of metastatic melanoma
    Sharma, KV; Gould, JE; Harbour, JW
  • Development of isolated hepatic perfusion via the operative and percutaneous techniques for patients with isolated and unresectable liver metastases
    Alexander, HR; Butler, CC
  • Treatment of melanoma metastases confined to the liver and future perspectives
    Vahrmeijer, AL; Velde, CJH; Hartgrink, HH; Tollenaar, RAEM
  • A phase I-II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver
    Alexander, HR; Libutti, SK; Bartlett, DL; Puhlmann, M; Fraker, DL; Bachenheimer, LC
  • Hyperthermic isolated hepatic perfusion using melphalan for patients with ocular melanoma metastatic to liver
    Alexander, HR; Libutti, SK; Pingpank, JF
  • Isolated hepatic perfusion with 200 mg melphalan for advanced noncolorectal liver metastases
    Iersel, LB; Hoekman, EJ; Gelderblom, H
  • Results of a randomized controlled multicenter phase III trial of percutaneous hepatic perfusion compared with best available care for patients with melanoma liver metastases
    Hughes, MS; Zager, J; Faries, M
  • Phase II evaluation of temozolomide in metastatic choroidal melanoma
    Bedikian, AY; Papadopoulos, N; Plager, C; Eton, O; Ring, S
  • Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in patients with metastatic uveal melanoma
    Homsi, J; Bedikian, AY; Papadopoulos, NE
  • Bleomycin, vincristine, lomustine and dacarbazine (BOLD) in combination with recombinant interferon alpha-2b for metastatic uveal melanoma
    Kivelä, T; Suciu, S; Hansson, J
  • A prospective single arm phase II study of dacarbazine and treosulfan as first-line therapy in metastatic uveal melanoma
    O’Neill, PA; Butt, M; Eswar, CV; Gillis, P; Marshall, E
  • Treosulfan and gemcitabine in metastatic uveal melanoma patients: results of a multicenter feasibility study
    Pföhler, C; Cree, IA; Ugurel, S
  • Metastatic uveal melanoma: is there a role for conventional chemotherapy? A single center study based on 58 patients
    Pons, F; Plana, M; Caminal, JM
  • Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD), and human leukocyte interferon for metastatic uveal melanoma
    Pyrhönen, S; Hahka-Kemppinen, M; Muhonen, T
  • Phase II trial of cisplatin, gemcitabine and treosulfan in patients with metastatic uveal melanoma
    Schmittel, A; Scheulen, ME; Bechrakis, NE
  • A two-cohort phase II clinical trial of gemcitabine plus treosulfan in patients with metastatic uveal melanoma
    Schmittel, A; Schuster, R; Bechrakis, NE
  • Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy
    Danielli, R; Ridolfi, R; Chiarion-Sileni, V
  • Overexpression of the KIT/SCF in uveal melanoma does not translate into clinical efficacy of imatinib mesylate
    Hofmann, UB; Kauczok-Vetter, CS; Houben, R; Becker, JC
  • A pilot study of sunitinib malate in patients with metastatic uveal melanoma
    Mahipal, A; Tijani, L; Chan, K; Laudadio, M; Mastrangelo, MJ; Sato, T
  • Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma
    Carvajal, RD; Sosman, JA; Quevedo, JF
  • Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies
    Algazi, AP; Tsai, KK; Shoushtari, AN